PDF(Pubmed)
Abstract：
UNASSIGNED: Sarcopenia is associated with worsened outcomes in solid cancers. Temporalis muscle thickness (TMT) has emerged as a measure of sarcopenia. Hence, this study aims to evaluate the relationship between TMT and outcome measures in patients with malignant intra-axial neoplasms.
UNASSIGNED: We searched Medline, Embase, Scopus and Cochrane databases for relevant studies. Event ratios with 95% confidence intervals (CI) were analysed using the RevMan 5.4 software. Where meta-analysis was impossible, vote counting was used to determine the effect of TMT on outcomes. The GRADE framework was used to determine the certainty of the evidence.
UNASSIGNED: Four outcomes were reported for three conditions across 17 studies involving 4430 patients. Glioblastoma: thicker TMT was protective for overall survival (OS) (HR 0.59; 95% CI 0.46-0.76) (GRADE low), progression free survival (PFS) (HR 0.40; 95% CI 0.26-0.62) (GRADE high), and early discontinuation of treatment (OR 0.408; 95% CI 0.168-0.989) (GRADE high); no association with complications (HR 0.82; 95% CI 0.60-1.10) (GRADE low). Brain Metastases: thicker TMT was protective for OS (HR 0.73; 95% CI 0.67-0.78) (GRADE moderate); no association with PFS (GRADE low). Primary CNS Lymphoma: TMT was protective for overall survival (HR 0.34; 95% CI 0.19-0.60) (GRADE moderate) and progression free survival (HR 0.23; 95% CI 0.09-0.56) (GRADE high).
UNASSIGNED: TMT has significant prognostic potential in intra-axial malignant neoplasms, showing a moderate to high certainty for its association with outcomes following GRADE evaluation. This will enable shared decision making between patients and clinicians.
UNASSIGNED: We searched Medline, Embase, Scopus and Cochrane databases for relevant studies. Event ratios with 95% confidence intervals (CI) were analysed using the RevMan 5.4 software. Where meta-analysis was impossible, vote counting was used to determine the effect of TMT on outcomes. The GRADE framework was used to determine the certainty of the evidence.
UNASSIGNED: Four outcomes were reported for three conditions across 17 studies involving 4430 patients. Glioblastoma: thicker TMT was protective for overall survival (OS) (HR 0.59; 95% CI 0.46-0.76) (GRADE low), progression free survival (PFS) (HR 0.40; 95% CI 0.26-0.62) (GRADE high), and early discontinuation of treatment (OR 0.408; 95% CI 0.168-0.989) (GRADE high); no association with complications (HR 0.82; 95% CI 0.60-1.10) (GRADE low). Brain Metastases: thicker TMT was protective for OS (HR 0.73; 95% CI 0.67-0.78) (GRADE moderate); no association with PFS (GRADE low). Primary CNS Lymphoma: TMT was protective for overall survival (HR 0.34; 95% CI 0.19-0.60) (GRADE moderate) and progression free survival (HR 0.23; 95% CI 0.09-0.56) (GRADE high).
UNASSIGNED: TMT has significant prognostic potential in intra-axial malignant neoplasms, showing a moderate to high certainty for its association with outcomes following GRADE evaluation. This will enable shared decision making between patients and clinicians.
摘要：
■肌肉减少症与实体癌预后恶化相关。颞肌厚度（TMT）已成为衡量肌肉减少症的指标。因此，本研究旨在评估恶性轴内肿瘤患者的TMT与预后指标之间的关系.
■我们搜索了Medline，Embase,Scopus和Cochrane数据库进行相关研究。使用RevMan5.4软件分析具有95%置信区间(CI)的事件比率。在无法进行荟萃分析的地方，投票计数用于确定TMT对结果的影响。等级框架用于确定证据的确定性。
■在涉及4430名患者的17项研究中，报告了3项疾病的4项结果。胶质母细胞瘤：较厚的TMT对总生存期（OS）具有保护作用（HR0.59;95％CI0.46-0.76）（等级低），无进展生存期（PFS）（HR0.40；95%CI0.26-0.62）（分级高），和早期停止治疗（OR0.408;95％CI0.168-0.989）（等级高）；与并发症无关（HR0.82;95％CI0.60-1.10）（等级低）。脑转移：较厚的TMT对OS具有保护作用（HR0.73;95％CI0.67-0.78）（中度）；与PFS无关（低等级）。原发性中枢神经系统淋巴瘤：TMT对总生存期（HR0.34；95％CI0.19-0.60）（中度）和无进展生存期（HR0.23；95％CI0.09-0.56）（高度）具有保护作用。
■TMT在轴内恶性肿瘤中具有重要的预后潜力，显示其与GRADE评估后结果的相关性具有中等到高度的确定性。这将使患者和临床医生之间的共同决策成为可能。
■我们搜索了Medline，Embase,Scopus和Cochrane数据库进行相关研究。使用RevMan5.4软件分析具有95%置信区间(CI)的事件比率。在无法进行荟萃分析的地方，投票计数用于确定TMT对结果的影响。等级框架用于确定证据的确定性。
■在涉及4430名患者的17项研究中，报告了3项疾病的4项结果。胶质母细胞瘤：较厚的TMT对总生存期（OS）具有保护作用（HR0.59;95％CI0.46-0.76）（等级低），无进展生存期（PFS）（HR0.40；95%CI0.26-0.62）（分级高），和早期停止治疗（OR0.408;95％CI0.168-0.989）（等级高）；与并发症无关（HR0.82;95％CI0.60-1.10）（等级低）。脑转移：较厚的TMT对OS具有保护作用（HR0.73;95％CI0.67-0.78）（中度）；与PFS无关（低等级）。原发性中枢神经系统淋巴瘤：TMT对总生存期（HR0.34；95％CI0.19-0.60）（中度）和无进展生存期（HR0.23；95％CI0.09-0.56）（高度）具有保护作用。
■TMT在轴内恶性肿瘤中具有重要的预后潜力，显示其与GRADE评估后结果的相关性具有中等到高度的确定性。这将使患者和临床医生之间的共同决策成为可能。
